Description

CABLIZ 0.25 MG

Indications

CABLIZ 0.25 MG, containing the active ingredient cabozantinib, is primarily indicated for the treatment of advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy. Additionally, CABLIZ is also approved for the treatment of hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib. The medication is utilized in cases where the disease has progressed despite prior treatments, offering a new therapeutic option for patients with limited alternatives.

Mechanism of Action

The therapeutic efficacy of CABLIZ is attributed to its role as a multi-kinase inhibitor. Cabozantinib targets several receptor tyrosine kinases, including MET, VEGFR, and AXL, which are implicated in tumor growth, angiogenesis, and metastasis. By inhibiting these pathways, CABLIZ disrupts the signaling processes that facilitate cancer cell proliferation and survival. This action not only reduces tumor growth but also potentially enhances the body’s immune response against cancer cells.

Pharmacological Properties

CABLIZ is characterized by its pharmacokinetic profile, which includes a peak plasma concentration occurring approximately 2 to 6 hours after oral administration. The bioavailability of cabozantinib is approximately 20%, and it is highly protein-bound (99.7%). The drug is metabolized primarily by the liver through cytochrome P450 enzymes, particularly CYP3A4, and has a half-life of approximately 55 hours. This extended half-life allows for once-daily dosing, which can improve patient compliance.

Contraindications

CABLIZ is contraindicated in patients with a known hypersensitivity to cabozantinib or any of its excipients. Additionally, it should not be used in patients with severe hepatic impairment (Child-Pugh Class C) due to the increased risk of adverse effects and altered pharmacokinetics. Pregnant or breastfeeding women should also avoid CABLIZ, as its safety in these populations has not been established.

Side Effects

Common side effects associated with CABLIZ include fatigue, diarrhea, nausea, vomiting, decreased appetite, and weight loss. More serious adverse effects may include hypertension, liver function abnormalities, and gastrointestinal perforations. Patients should be monitored for these potential side effects, and appropriate management strategies should be implemented as necessary. It is essential to inform patients about the possibility of these side effects and the importance of reporting any unusual symptoms promptly.

Dosage and Administration

The recommended starting dose of CABLIZ is 60 mg taken orally once daily, preferably at the same time each day. The tablets should be swallowed whole with water and should not be crushed or chewed. Dose adjustments may be necessary based on individual tolerability and the occurrence of adverse effects. If a dose is missed, it should be taken as soon as possible on the same day; however, if it is close to the time of the next scheduled dose, the missed dose should be skipped, and the patient should resume their regular dosing schedule.

Interactions

CABLIZ may interact with various medications, particularly those that are metabolized by the liver. Strong CYP3A4 inhibitors, such as ketoconazole and ritonavir, can increase cabozantinib levels, necessitating dose adjustments. Conversely, strong CYP3A4 inducers, such as rifampicin and St. John’s Wort, may decrease cabozantinib levels, potentially reducing its efficacy. Patients should be advised to inform their healthcare provider about all medications, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions

Before initiating treatment with CABLIZ, a thorough assessment of the patient’s medical history should be conducted. Special caution should be exercised in patients with a history of cardiovascular disease, as CABLIZ may exacerbate hypertension and lead to serious cardiovascular events. Regular monitoring of blood pressure is recommended, and antihypertensive therapy should be initiated if necessary. Additionally, liver function tests should be performed periodically, as CABLIZ can cause hepatotoxicity.

Clinical Studies

Clinical trials have demonstrated the efficacy of CABLIZ in treating advanced RCC and HCC. In a pivotal Phase 3 trial for RCC, cabozantinib significantly improved progression-free survival compared to everolimus, with a median progression-free survival of 7.4 months versus 3.9 months, respectively. In patients with HCC, CABLIZ showed a significant improvement in overall survival compared to sorafenib, with a median overall survival of 10.2 months versus 8.0 months. These studies underscore the role of CABLIZ as a viable treatment option in advanced malignancies.

Conclusion

CABLIZ 0.25 MG represents an important advancement in the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. Its unique mechanism of action and clinical efficacy provide a valuable option for patients who have exhausted other treatment avenues. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for optimizing patient outcomes. Ongoing research and clinical experience will continue to define the role of CABLIZ in oncology.